Recombinant zoster vaccine administration in an allergy and immunology practice: A medical and economic case

Ann Allergy Asthma Immunol. 2020 May;124(5):517-518. doi: 10.1016/j.anai.2020.02.006. Epub 2020 Feb 21.

Authors

Hannah G Russell¹, Mike S Tankersley²

Affiliations

¹ Departments of Medicine, Pediatrics and Otolaryngology, University of Tennessee Health Science Center, Memphis, Tennessee.
² Departments of Medicine, Pediatrics and Otolaryngology, University of Tennessee Health Science Center, Memphis, Tennessee. Electronic address: mtanker6@uthsc.edu.

PMID: 32088321
DOI: 10.1016/j.anai.2020.02.006

No abstract available

Publication types

Letter

MeSH terms

Adult
Allergy and Immunology*
Costs and Cost Analysis
Female
Herpes Zoster / economics
Herpes Zoster / epidemiology
Herpes Zoster / immunology*
Herpes Zoster Vaccine / immunology*
Herpesvirus 3, Human / physiology*
Humans
Hypersensitivity / economics
Hypersensitivity / epidemiology
Hypersensitivity / immunology*
Insurance, Health, Reimbursement
Lipid A / analogs & derivatives
Lipid A / immunology
Male
Mass Vaccination / economics*
Middle Aged
Practice Guidelines as Topic
Saponins / immunology
United States / epidemiology
Vaccines, Synthetic
Viral Envelope Proteins / genetics
Viral Envelope Proteins / immunology*

Substances

AS01B adjuvant
Herpes Zoster Vaccine
Lipid A
Saponins
Vaccines, Synthetic
Viral Envelope Proteins
glycoprotein E, varicella-zoster virus